Table 1 Patient characteristics
Characteristic | No. |
|---|---|
Median age/years (range) | 73 (59–87) |
Gender (n=) | |
Male/female | 19/5 |
Diagnosis (FAB) (n=) | |
RAEB | 8 |
RAEB-T | 3 |
CMML | 2 |
AML | 11 |
Diagnosis (WHO) (n=) | |
RAEB II | 4 |
CMML II | 2 |
AML, de novo | 6 |
sAML/MDS | 7 |
AML/MDS, therapy-related | 5 |
IPSS-risk group (n=) | |
Intermediate II | 5 |
High | 9 |
Karyotype-risk (IPSS) (n=) | |
Good | 9 |
Intermediate | 4 |
Poor | 11 |
Karyotype risk (AML1) (n=) | |
Good | 0 |
Intermediate | 12 |
Poor | 12 |
Karyotype (n=) | |
Normal | 7 |
Abnormal | 17 |
Median marrow blast count (%) | 18 (1–80) |
Pre-treatment (n=) | |
Intensive chemotherapy | 1 |
Hydroxyurea | 3 |
LBH-589 | 3 |
VPA (+/− ATRA) | 2 |
Growth factors | 2 |
None | 2 |
Transfusion dependency | |
Yes/no | 19/5 |
Median WBC/μl | 2,245 (400–32,000) |
WBC > 10.000 (n=) | 5 |
WBC < 1,800 | 20 |
WBC < 500 | 7 |
Median platelet count/μl | 57,000 (5,000–252,000) |
Platelets < 100,000 (n=) | 17 |
Platelets < 30,000 | 9 |